Boston Scientific Corporation $BSX Stock Holdings Cut by J. Safra Sarasin Holding AG

Key Points

• J. Safra Sarasin reduced its stake in Boston Scientific by 11.8% to 270,465 shares (worth $25.79M), and institutional investors collectively own about 89.07% of BSX.
• Analysts have lowered price targets and issued downgrades (e.g., Oppenheimer $125→$100, Stifel $110→$90), and mixed/underwhelming Watchman trial data plus regulatory/legal overhangs helped trigger a near-term sell-off that pushed BSX down about 9.1% to $62.90.
• CEO Michael F. Mahoney sold 160,901 shares (~10.23% of his holding) for roughly $15.04M, even as the company reported a small EPS beat, 15.9% revenue growth for the quarter, and FY2026 guidance of $3.43–$3.49.

J. Safra Sarasin Holding AG lessened its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 11.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 270,465 shares of the medical equipment provider's stock after selling 36,293 shares during the period. J. Safra Sarasin Holding AG's holdings in Boston Scientific were worth $25,789,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of BSX. Vanguard Group Inc. grew its holdings in Boston Scientific by 0.8% during the third quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider's stock worth $13,497,294,000 after acquiring an additional 1,115,337 shares during the period. State Street Corp boosted its position in shares of Boston Scientific by 1.1% during the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider's stock valued at $7,002,258,000 after purchasing an additional 713,379 shares in the last quarter. Invesco Ltd. grew its stake in shares of Boston Scientific by 0.7% in the 3rd quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider's stock worth $1,656,131,000 after purchasing an additional 111,826 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Boston Scientific by 0.9% in the 3rd quarter. Northern Trust Corp now owns 14,402,636 shares of the medical equipment provider's stock worth $1,406,129,000 after purchasing an additional 128,188 shares in the last quarter. Finally, Amundi boosted its holdings in Boston Scientific by 17.5% during the third quarter. Amundi now owns 11,981,584 shares of the medical equipment provider's stock worth $1,158,619,000 after buying an additional 1,781,830 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Oppenheimer dropped their price target on Boston Scientific from $125.00 to $100.00 and set an "outperform" rating on the stock in a report on Friday, January 16th. Stifel Nicolaus decreased their target price on Boston Scientific from $110.00 to $90.00 and set a "buy" rating on the stock in a report on Friday, March 20th. Truist Financial cut their target price on Boston Scientific from $95.00 to $92.00 and set a "buy" rating on the stock in a research report on Wednesday, March 18th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Boston Scientific in a report on Monday, March 16th. Finally, Weiss Ratings lowered Boston Scientific from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat, Boston Scientific currently has an average rating of "Moderate Buy" and an average price target of $104.36.

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company's stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares of the company's stock, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.34% of the company's stock.

Boston Scientific Stock Down 9.1%

Shares of NYSE:BSX opened at $62.90 on Tuesday. The firm has a 50 day simple moving average of $76.94 and a 200 day simple moving average of $90.32. Boston Scientific Corporation has a 52 week low of $61.24 and a 52 week high of $109.50. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The company has a market cap of $93.49 billion, a PE ratio of 32.42, a price-to-earnings-growth ratio of 1.07 and a beta of 0.69.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. The firm had revenue of $5.29 billion for the quarter, compared to analysts' expectations of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company's quarterly revenue was up 15.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: FDA clearance for the Asurys fluid management system gives Boston Scientific another regulatory win and supports growth in perioperative/OR product offerings. Boston Scientific wins FDA clearance for fluid management system
• Positive Sentiment: Strong HI-PEITHO trial results for the EKOS endovascular system (positive readout reported) bolster the company’s pulmonary embolism franchise and provide clinical momentum for EKOS adoption. Boston Scientific Reports Strong HI-PEITHO Trial Results for EKOS
• Positive Sentiment: Several analysts reaffirm buy/outperform ratings and high price targets (Needham, TD Cowen, RBC), reflecting confidence in long-term growth drivers like Watchman FLX and diversified product mix. Buy Rating on Boston Scientific’s Watchman FLX
• Neutral Sentiment: Company set an investors’ conference call for the Q1 2026 results (April 22), which will be a key event for management to clarify guidance, procedure trends and margin outlook. Boston Scientific announces conference call
• Neutral Sentiment: Analysts expect single-digit EPS growth for Q1 2026; Q1 results and any guidance update will likely drive near-term volatility but may not change the long-term thesis. Boston Scientific's Q1 2026 Earnings: What to Expect
• Negative Sentiment: Mixed/underwhelming clinical data for the Watchman device (conflicting trial readouts) is the proximate trigger for today’s sell-off as investors reprice stroke-prevention growth expectations. Boston Scientific Falls After Underwhelming Trial Results
• Negative Sentiment: Raymond James downgraded BSX and cut its price target, and Goldman trimmed its target as well — analyst downgrades and lower PTs pressured sentiment and valuation multiples. Shares Plunge After Raymond James Downgrade
• Negative Sentiment: Heightened legal/regulatory overhang — multiple investor alerts and class-action filings tied to prior disclosures are creating uncertainty and may keep pressure on the stock until resolved. BSX Investor Alert: Securities Fraud Lawsuit

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.